RE: CRC Blood Test AccuratelyDetects both Cancer and Polyps5 Feb 2025 09:21
Globally, CRC is the third most common cancer type, accounting for 10% of all cancer cases. There were 1.9 million new cases and 930,000 deaths from the disease in 2020. More than 80% of CRC arises from adenomatous polyps and outgrowths. Around 75-95% of CRC cases occur in people with little or no genetic risk. Screening modalities such as colonoscopy, faecal immunochemical tests (FIT), FIT-DNA and cell-free DNA from CRC tumours in blood are current primary screening tests for early detection and prevention. Unfortunately, the non-invasive methods lack sensitivity to polyps and early CRC.
OBD’s EpiSwitch pipeline development has delivered a blood-based Colorectal No-Stool Test (NST) which shows significant potential as an accurate and rapid cancer screening diagnostic for early stages of cancer (sensitivity 84% and specificity 79%) and non-cancerous polyps (sensitivity 79% and specificity 83%). This accurate, rapid, minimally invasive, and cost-effective NST test was built using OBD’s EpiSwitch® 3D genomics platform and methodology. For each patient, NST captures a personal, systemic fingerprint of specific regulatory network changes associated with early stages of colorectal cancer and/or non-cancerous polyps.
Sign In
Follow the stocks
